AI assistant
Sending…
MILESTONE SCIENTIFIC INC. — Director's Dealing 2003
Oct 2, 2003
34735_dirs_2003-10-02_c757e11d-7ff0-4b8f-99ea-b18267658ece.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MILESTONE SCIENTIFIC INC/NJ (MS)
CIK: 0000855683
Period of Report: 2003-09-30
Reporting Person: OSSER LEONARD (Director, Chief Executive Officer, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2003-09-30 | Common Stock .001 par value | P | 400454 | $404459 | Acquired | 3265698 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to purchase common stock | $1.00 | 2004-01-09 | Common Stock .001 par value (50000) | 50000 | Direct |
| Options to Purchase Common Stock | $.875 | 2005-01-01 | Common Stock .001 Par Value (50000) | 50000 | Direct |
| Options to Purchase Common Stock | $2.00 | 2006-01-04 | Common Stock .001 Par Value (50000) | 50000 | Direct |
| Options to Purchase Common Stock | $.68 | 2007-01-02 | Common Stock .001 Par Value (50000) | 50000 | Direct |
| Options to Purchase Common Stock | $1.75 | 2005-02-01 | Common Stock .001 Par Value (35714) | 35714 | Direct |
| Options to Purchase Common Stock | $ | 2007-01-31 | Common Stock .001 Par Value (614183) | 614183 | Direct |
Footnotes
F1: Options to purchase common stock * 1/2/02 A A 1/2/02 1/31/07 Common Stock par value $.001 614,183 D
*The exercise price for any of these option is $.80 through 1/31/03, $1.00 from 2/1/03 through 1/31/06 and $2.00 from 2/1/06 through 1/31/07
More from MILESTONE SCIENTIFIC INC.
Regulatory Filings
2026
Jun 2
Interim / Quarterly Report
2026
May 13
Regulatory Filings
2026
May 6
Board/Management Information
2026
May 6
Annual Report
2026
May 5
Regulatory Filings
2026
Apr 23
Capital/Financing Update
2026
Apr 21
Regulatory Filings
2026
Apr 2
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 10